calcipotriol/betamethasone sandoz 50 mikrog/ g / 0.5 mg/ g
sandoz - københavn - kalsipotriolmonohydrat / betametasondipropionat - salve - 50 mikrog/ g / 0.5 mg/ g
calcipotriol/betamethasone aristo 50 mikrog/ g / 0.5 mg/ g
aristo pharma gmbh - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g
calcipotriol/betamethasone orifarm 50 mikrog/ g / 0.5 mg/ g
orifarm generics a/s - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g
advantan 0.1 % emulsiovoide
leo pharma a/s - methylprenisolone aceponate - emulsiovoide - 0.1 % - metyyliprednisoloniaseponaatti
daivobet 50 / 500 mikrog/g voide
leo pharma a/s - calcipotriol hydrate, betamethasone dipropionate - voide - 50 / 500 mikrog/g - kalsipotrioli
hydraderm 1 % emulsiovoide
evolan pharma ab - hydrocortisonum - emulsiovoide - 1 % - hydrokortisoni
clobex 500 mikrog/ g
galderma nordic ab - klobetasolpropionat - sjampo - 500 mikrog/ g
fucidin-hydrocortison 20 mg/ g / 10 mg/ g
leo pharma - fusidinsyrehemihydrat / hydrokortisonacetat - krem - 20 mg/ g / 10 mg/ g
intrinsa
warner chilcott uk ltd. - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - intrinsa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
livensa
warner chilcott deutschland gmbh - testosterone - sexual dysfunctions, psychological - sex hormones and modulators of the genital system, - livensa is indicated for the treatment of hypoactive sexual desire disorder (hsdd) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.